3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Breast Neoplasms
20
Carcinoma, Non-Small-Cell Lung
19
Pancreatic Neoplasms
17
Triple Negative Breast Neoplasms
16
Neoplasm Metastasis
9
Parkinson Disease 4, Autosomal Dominant Lewy Body
6
Neoplasms
5
Lung Neoplasms
4
Carcinoma
4
Neoplasms by Site
3
Adenocarcinoma
3
Pancreatic Diseases
2
Ovarian Neoplasms
2
Neoplasms by Histologic Type
2
Fallopian Tube Neoplasms
2
Endocrine System Diseases
2
Endocrine Gland Neoplasms
2
Digestive System Neoplasms
2
Digestive System Diseases
2
Carcinoma, Pancreatic Ductal
2
Carcinoma, Ductal, Breast
2
Vaccinia
1
Thromboembolism
1
Thoracic Neoplasms
1
Squamous Non-Small Cell Lung Cancer
1
Squamous Cell Carcinoma of Head and Neck
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Peritoneal Neoplasms
1
Pancreatic cancer, adult
1
Interventions
Paclitaxel
25
Doxorubicin
15
Carboplatin
14
pembrolizumab
10
Cisplatin
8
Radiotherapy
6
Docetaxel
5
Chemotherapy, Adjuvant
5
Taxes
4
Filgrastim
4
Brachytherapy
4
lenvatinib
3
Observation
3
trastuzumab deruxtecan
2
selinexor
2
olaparib
2
durvalumab
2
Tamoxifen
2
Specimen Handling
2
Ifosfamide
2
Drug Therapy
2
sintilimab
1
sacituzumab govitecan
1
pertuzumab
1
nanocis
1
liposomal doxorubicin
1
ixabepilone
1
gallium-diethylenetriaminepentaacetic acid-mannosyl-dextran
1
dostarlimab
1
atezolizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Endometrial Neoplasms
×
130-nm albumin-bound paclitaxel
×
Clear all
NCT06132958
2026-04-03
TroFuse-005
Merck Sharp & Dohme LLC
Phase 3
Active not recruiting
710 enrolled